卵巢癌评分用于诊断卵巢癌的多中心研究
这项多中心研究纳入中国四家医院1183例附件包块成年女性,前瞻性收集1024例、生物样本库159例,术前检测血清小细胞外囊泡CA125、HE4和C5a并计算卵巢癌评分(OCS)。前瞻队列中OCS诊断卵巢癌的灵敏度95.4%、特异度90.4%,全部病例中分别为95.5%和90.2%,在绝经状态和FIGO分期间表现稳定。
要点
- OCS诊断卵巢癌前瞻队列灵敏度95.4%、特异度90.4%(n=1024)。
- 全部病例灵敏度95.5%、特异度90.2%(n=1183)。
- 早期上皮性卵巢癌FIGO I期灵敏度89.7%、I+II期91.4%。
核心结论
- 这项多中心研究显示,OCS是检测卵巢癌有前景的无创诊断工具。
研究设计与样本
- 多中心研究纳入中国四家医院2019年10月至2023年4月1183例附件包块成年女性,其中1024例样本前瞻性收集、159例来自生物样本库。
- 所有血清样本均在手术前采集,采用化学发光免疫分析法检测sEV CA125、HE4和C5a浓度并计算OCS。
- 研究注册于ClinicalTrials.gov:NCT06366997。
主要发现
- 前瞻队列(n=1024)中OCS诊断卵巢癌的灵敏度95.4%、特异度90.4%;全部病例(n=1183)中灵敏度95.5%、特异度90.2%。
- OCS在绝经状态和FIGO分期间表现稳定,绝经前患者特异度89.6%、绝经后患者特异度92.1%。
- 早期上皮性卵巢癌中OCS灵敏度较高:FIGO I期89.7%、I+II期91.4%。
- 年龄≤45岁患者灵敏度92.7%,CA125正常患者灵敏度72.7%;原文指出这些结果来自小样本亚组。
局限性
- 原文指出早期上皮性卵巢癌、年龄≤45岁及CA125正常患者的亚组结果来自小样本亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early detection is crucial for improving survival of patients with ovarian cancer (OC), yet current diagnostic tools lack adequate sensitivity and specificity, especially for early stage disease. The study aimed to validate the serum small extracellular vesicles (sEV) protein based Ovarian Cancer Score (OCS) in detecting OC. METHODS: This multicenter study included 1183 adult females with adnexal masses from four hospitals in China (October 2019-April 2023). Of these, 1024 samples were prospectively collected, and 159 were from biobanks. All serum samples were collected before surgery. The concentrations of sEV carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), and complement component 5a protein (C5a) were quantified using chemiluminescence immunoassay and then used for calculating OCS. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. RESULTS: The OCS demonstrated high sensitivity (95.4 %) and specificity (90.4 %) in diagnosis of OC in the prospective cohort (n = 1024) and in total cases (n = 1183, 95.5 % and 90.2 %), with stable performance across menopausal status and FIGO stages. The OCS maintained a high specificity in premenopausal patients (89.6 %) and postmenopausal patients (92.1 %). The OCS showed high sensitivity in early stage epithelial OC (FIGO I: 89.7 %, I + II: 91.4 %), in patients aged ≤45 years (92.7 %), and in patients with normal CA125 levels (72.7 %), although these results were obtained from subgroups with small sample sizes. CONCLUSION: This multicenter study demonstrated that the OCS is a promising non-invasive diagnostic tool for the detection of OC. TRIAL REGISTRY: This study was registered at ClinicalTrials.gov: NCT06366997.
引用
- Wang H, Zhu J, Zou D, et al. Multicenter study of ovarian cancer score for diagnosing ovarian cancer. Gynecol Oncol. 2025. PMID: 39793443. doi:10.1016/j.ygyno.2024.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。